查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190626

DNA 測序市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Dna Sequencing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 131 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2021 年 DNA 測序市場價值約為 104.954 億美元，到 2027 年將達到 238.8565 億美元，預計在預測期內（2022-2027 年）複合年增長率為 18.61%。

COVID-19 大流行對研究中的市場產生了積極影響，因為它增加了治療和診斷開發中對 DNA 測序技術的需求。 例如，2020 年 8 月，Helix COVID-19 NGS 測試獲得了 FDA 的緊急使用授權（EUA）批准，僅適用於 Helix Laboratories。 這是一種基於擴增子的下一代測序 (NGS) 測試，用於定性檢測疑似 COVID-19 感染者的上呼吸道標本中的 SARS-CoV-2 核酸。 因此，由於在開發 COVID-19 的診斷工具和有效治療方法中基於 DNA 測序的研發活動不斷增加，預計市場在預測期內將保持顯著增長率。

推動市場增長的某些因素包括 DNA 測序技術的進步、臨床診斷和藥物發現應用的增加，以及研發投資的增加。 DNA 測序在診斷學、個性化醫療、生物標誌物、法醫學、生殖醫學等方面都有應用。 ] DNA測序技術在癌症診斷和治療的臨床研究和開發中具有巨大的潛力。 近年來，下一代測序 (NGS) 技術已證明其作為一種高通量且廉價的方法能夠在單次測試中識別和表徵大量基因的臨床可操作遺傳改變。 根據Hong-Yan Liu等人發表於Scientific Reports Journal 2019的研究論文，估計80%的罕見病是由基因引起的，因此基於基因組測序的診斷是罕見病管理的重要工具。它提供了一個有前途的替代方案，預計將對市場產生積極影響。 因此，預計 DNA 測序在臨床診斷和藥物發現中的應用越來越多，將在預測期內推動市場增長。

從 20 世紀 70 年代的二維測序到 DNA 測序，測序技術取得了長足的進步。 近年來，Illumina/Solexa、ABI/SOLiD、454/Roche 和 Helicos 等平台為高通量功能基因組學研究提供了獨特的視角。 此外，生物學家和信息學專業人士專注於開發更好的基因組，新的測序技術、識別染色體序列的新方法以及 DNA 測序軟件的改進使之成為可能。我猜

新一代測序 (NGS) 技術作為常規臨床診斷測試也越來越受歡迎，尤其是在 COVID-19 大流行期間，它對市場產生了積極影響。 因此，DNA 測序技術的不斷進步正在促進調查市場的增長。

主要市場趨勢

下一代測序領域有望在預測期內主導市場

下一代測序領域的驅動因素包括 NGS 應用的增加、速度、成本、準確性、傳統技術的有效替代方案，以及需要 NGS 技術的藥物發現應用。 這項技術的優勢在於它更便宜、更快並且需要更少的 DNA，從而有助於整個細分市場的增長。

COVID-19 大流行增加了下一代測序技術在傳染病診斷中的應用，因為它具有高效率和準確性。 2020 年 6 月，FDA 為其產品 COVIDSeq 測試授予 Illumina 緊急使用授權，這是第一個利用下一代測序技術的 COVID-19診斷測試。 使用二代測序進行檢測的優勢在於，它可以檢測樣本中是否存在病毒，同時生成有關樣本中病毒基因組序列的信息。 該基因組信息可用於研究目的，從而支持市場增長。

醫療領域擁有各種技術進步並且正在快速發展，導致個性化醫療的發展。 下一代測序在個性化醫療中的應用數量巨大。 2020 年 5 月，瑞典生物技術公司 CARTANA 擴展了其用於高通量單細胞基因表達圖譜的原位測序試劑盒系列。 2020 年 10 月，Bio-Rad Laboratories Inc. 宣布推出 SEQuoia Complete Stranded RNA Library Prep Kit，這是一種新的 RNA-Seq 文庫製備方法。 因此，個性化醫療的進步為 NGS 應用開闢了許多途徑，並可能加速該領域的發展。

推出和改進，以及對這項技術的好處和不斷增長的需求，是細分市場增長的主要驅動力。 例如，Thermo Fisher Scientific 於 2019 年 11 月推出了 Ion Torrent Genexus 系統。 它是第一個完全集成的下一代測序 (NGS) 平台，具有自動化的樣本到報告工作流程，可在一天內提供經濟的結果。 因此，由於上述因素，預計該細分市場將在預測期內增長。

北美主導市場，預計在預測期內也會如此

由於政府和非政府組織（尤其是在美國）增加的資金和宣傳，北美在市場上佔據主導地位。 越來越多地採用先進技術以及政府和相關政策的有利支持是該國 DNA 測序的主要驅動力。

COVID-19 大流行病的興起也對市場增長產生了積極影響。 例如，2020 年 4 月，加拿大基因組啟動了加拿大 COVID 基因組學網絡 (CanCOGeN)，這是一項由 4000 萬美元資金支持的新成立計劃。 在加拿大基因組的領導下，CanCOGeN 將與六個區域基因組中心、國家和省級公共衛生實驗室、通過 CGEn 的基因組測序中心、醫院、大學和私營部門合作，將在加拿大提供基於基因組的 COVID-19 研究。我們計劃擴大我們的研究。

此外，與美國國家人類基因組研究所 (NHGRI) 一樣，我們在支持與解碼人類基因組相關的研究的同時，還資助基因組在健康和疾病中的結構、功能和作用的研究。還有各種政府機構， 此外，這些組織還支持對基因組研究的倫理、法律和社會影響的研究。

競爭格局

DNA 測序市場競爭激烈，由幾家大型企業組成。 Agilent Technologies Inc.、Bio-Rad Laboratories Inc.、Danaher Corporation、Eurofins Scientific、F. Hoffmann-La Roche、Illumina Inc.、Merck KGaA、Pacific Biosciences of California Inc、PerkinElmer Inc、Thermo Fisher Scientific Inc.等公司。在 DNA 測序市場佔有相當大的份額。 這些公司正在努力滿足不斷增長的消費者需求，並在生產、分銷和全面質量控制方面進行了大量投資，以擴大其產品組合。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 調查結果
  • 調查假設
  • 本次調查的範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • DNA 測序技術不斷進步
    • 在臨床診斷和藥物發現方面的應用有所增加
    • 增加研發投資
  • 市場製約因素
    • 複雜的數據解釋和缺乏熟練的專業人員
    • 法律和道德問題
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（按價值計算的市場規模：百萬美元）

  • 產品類型
    • 設備
    • 耗材（試劑盒、試劑）
    • 其他產品類型
  • 測序類型
    • 桑格測序
    • 下一代測序
    • 其他排序類型
  • 應用領域
    • 診斷
    • 個性化醫療
    • 其他應用
  • 最終用戶
    • 醫院和醫療保健機構
    • 學術和研究機構
    • 製藥和生物技術公司
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation（Integrated DNA Technologies Inc.）
    • F. Hoffmann-La Roche Ltd
    • Illumina Inc.
    • Merck KGaA
    • PerkinElmer Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Macrogen Inc.
    • Myriad Genetics Inc.
    • Intrexon Bioinformatics Germany GmbH
    • Eurofins Scientific
    • Hamilton Thorne Biosciences
    • Pacific Biosciences of California Inc.

第7章 市場機會與今後動向

簡介目錄
Product Code: 66764

The DNA sequencing market was valued at approximately USD 10,409.54 million in 2021, and it is expected to reach USD 23,885.65 million by 2027, registering a CAGR of 18.61% during the forecast period (2022-2027).

The COVID-19 pandemic had a positive impact on the market studied, as it increased the demand for DNA sequencing technology in the development of therapeutics and diagnostics. For instance, in August 2020, the Helix COVID-19 NGS test was authorized by FDA under an Emergency Use Authorization (EUA) for use only by Helix Laboratory; it is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19 infection. Hence, owing to the increasing DNA sequencing-based research and development activities in the development of diagnostic tools or effective therapeutics for COVID-19, the market is likely to continue its significant growth rate during the forecast period.

Certain factors driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis and drug discovery, and growing investments in R&D. DNA sequencing has its applications in diagnostics, personalized medicine, biomarkers, forensics, reproductive health, and other applications. ] DNA sequencing technology holds great potential in the clinical research and development of cancer diagnostics and therapeutics. Recently, the next-generation sequencing (NGS) technology has demonstrated its capacity as a high-throughput and affordable approach to the identification and characterization of clinically actionable genetic variants across numerous genes at an exceptional speed in a single test. According to a research article by Hong-Yan Liu et al., published in the Scientific Reports Journal 2019, it has been estimated that 80% of rare diseases are genetic in origin, and thus, genome sequencing-based diagnosis offers a promising alternative for rare-disease management, which is expected to have a positive impact on the market. Therefore, the increasing application of DNA sequencing in clinical diagnosis and drug discovery is expected to drive the market growth over the forecast period.

The technological advancements in sequencing, from 2D sequencing in the 1970s to DNA sequencing, have come a long way. In recent years, platforms such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos have provided unique prospects for high-throughput functional genomic research. Moreover, biologists and informatics experts have been focusing on the development of better genomes, one made possible by newer sequencing technologies, novel methods for locating sequences on chromosomes, and improved software for DNA sequencing.

In addition, the next-generation sequencing (NGS) technology has been gaining popularity as a routine clinical diagnostic test, particularly with the COVID-19 pandemic, which has had a positive impact on the market. Thus, the increasing advancements in DNA sequencing technologies are contributing to the growth of the market studied.

Key Market Trends

The Next-generation Sequencing Segment is Expected to Dominate the Market During the Forecasted Period

The next-generation sequencing segment is being driven by factors such as the increasing applications of NGS, speed, cost, accuracy, efficient replacement of traditional technologies, and drug discovery applications demanding NGS technology. The advantage of this technology is that it is significantly cheaper, quicker, and needs significantly lesser DNA, which helps in the overall growth of the segment.

With the COVID-19 pandemic, there has been an increase in the adoption of next-generation sequencing technology in the diagnostics of infections, owing to its high efficiency and accuracy. In June 2020, the FDA issued an emergency use authorization to Ilumina Inc. for the product COVIDSeq Test, the first COVID-19 diagnostic test utilizing next-generation sequencing technology. The advantage of using a next-generation sequencing test is that it can generate information about the genomic sequence of the virus present in a sample along with detecting the presence of the virus in the sample. This genomic information can be used for research purposes, thus supporting the growth of the market.

There are various technological advancements in the field of medicine that are growing at a rapid pace and have led to the development of personalized medicine. There are a huge number of applications of next-generation sequencing in personalized medicine. In May 2020, the Swedish biotechnology company CARTANA launched an expanded range of In Situ Sequencing kits for high throughput single-cell gene expression mapping. In October 2020, Bio-Rad Laboratories Inc. announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit, a novel approach to RNA-Seq library preparation. Thus, the development of personalized medicine has opened many avenues for the application of NGS, which could accelerate the growth of the segment.

Along with the advantages of and increasing demand for this technology, the launches and advancements are huge boosters to the segment growth. For instance, Thermo Fisher Scientific launched its Ion Torrent Genexus System in November 2019, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. Hence, owing to the above-mentioned factors, the segment is expected to grow during the forecast period.

North America Dominates the Market, and It is Expected to do the Same During the Forecast Period

North America dominated the market due to the increase in funding and support activities by the government and non-government entities, especially in United States. The increasing adoption of advanced technologies and favorable support from the government and related policies are the primary driving factors for DNA sequencing in the country.

With the rising COVID-19 pandemic, there has been a positive impact on the market growth. For instance, in April 2020, Genome Canada launched the Canadian COVID Genomics Network (CanCOGeN), a newly formed initiative backed by funding of USD 40 million. Led by Genome Canada, in partnership with the six regional Genome Centers, national and provincial public health labs, genome sequencing centers through CGEn, hospitals, universities, and the private sector, CanCOGeN will scale up genomics-based COVID-19 research in Canada.

There are also various government bodies, like the US-based National Human Genome Research Institute (NHGRI), that have been supporting research related to human genome sequencing while funding research related to the genome's structure, function, and role in health and disease. Moreover, these organizations support studies on the ethical, legal, and social implications of genome research.

In December 2020, Illumina Inc. and Harvard Pilgrim Health Care announced a risk-sharing agreement to make whole-genome sequencing (WGS) available to certain Harvard Pilgrim members, effective January 2021. The program will leverage WGS to support faster diagnoses of genetic diseases in children, potentially eliminating the long, costly diagnostic process experienced by many families, with the goal of improving patient outcomes. In February 2020, MGI, part of the global genomics leader BGI Group, announced the commercial availability of its sequencing instruments and reagent kits in United States.

In November 2019, Thermo Fisher Scientific announced the launch of its Ion Torrent Genexus System, which is the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. ​ Hence, owing to these factors, the DNA sequencing market is expected to be one of the largest in the future.​

Competitive Landscape

The DNA sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc., Merck KGaA, Pacific Biosciences of California Inc., PerkinElmer Inc., and Thermo Fisher Scientific Inc., among others, hold substantial shares in the DNA sequencing market. These companies are making efforts to address the rising consumer demand and are significantly investing in production, distribution, and total quality management for the expansion of their portfolios.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Technological Advancements in DNA Sequencing
    • 4.2.2 Increasing Application in Clinical Diagnosis and Drug Discovery
    • 4.2.3 Growing Investments in R&D
  • 4.3 Market Restraints
    • 4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals
    • 4.3.2 Legal and Ethical Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Product Type
    • 5.1.1 Instruments
    • 5.1.2 Consumables (Kits and Reagents)
    • 5.1.3 Other Product Types
  • 5.2 Sequencing Type
    • 5.2.1 Sanger Sequencing
    • 5.2.2 Next-generation Sequencing
    • 5.2.3 Other Sequencing Types
  • 5.3 Application
    • 5.3.1 Diagnostics
    • 5.3.2 Personalized Medicine
    • 5.3.3 Other Applications
  • 5.4 End User
    • 5.4.1 Hospitals and Healthcare Organizations
    • 5.4.2 Academics and Research Institutions
    • 5.4.3 Pharmaceutical and Biotechnology Companies
    • 5.4.4 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies Inc.
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Danaher Corporation (Integrated DNA Technologies Inc.)
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Illumina Inc.
    • 6.1.6 Merck KGaA
    • 6.1.7 PerkinElmer Inc.
    • 6.1.8 Thermo Fisher Scientific Inc.
    • 6.1.9 QIAGEN
    • 6.1.10 Macrogen Inc.
    • 6.1.11 Myriad Genetics Inc.
    • 6.1.12 Intrexon Bioinformatics Germany GmbH
    • 6.1.13 Eurofins Scientific
    • 6.1.14 Hamilton Thorne Biosciences
    • 6.1.15 Pacific Biosciences of California Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS